Veronica Hulstrøm

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.

M. Ison, J. Langley, L. Cámpora, 2023, The New England journal of medicine.

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)

M. Ison, J. Langley, F. Martinón-Torres, 2022, Open Forum Infectious Diseases.

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

E. Kerwin, J. Tica, F. Struyf, 2022, The Journal of infectious diseases.

Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.

M. Haranaka, N. Mesaros, M. David, 2023, Respiratory investigation.

119. Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination

Shinn-Jang Hwang, M. Lievens, C. Liu, 2022, Open Forum Infectious Diseases.

96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination

Shinn-Jang Hwang, M. Lievens, C. Liu, 2022, Open Forum Infectious Diseases.